Genmab — Maj 2019
-
-
And I think we could potentially see partnerships for both of these programs to maximize the potential for the CD3xCD20, the very competitive hematological area. Now a little bit behind Roche and Regeneron but with a very differentiated molecule. This is given subcutaneously and preclinically. It's very, very much more potent than these other programs and we use a different way of silencing the bispecific. So we expect potentially less side effect issues than had been seen with this earlier
-
Som jeg tidligere har sagt, så handler det jo i bund og grund om man tror på GEN som vækstcase, og har tillid til det som JW fortæller om fremtiden. Ingen kan jo påstå præcist at vide det med sikkerhed. Jeg tror fuldt og fast på casen, og tager udsvingene i kursen med på rejsen. God dag
-
fra børsenhttps://borsen.dk/nyheder/virksomheder/artikel/1/381194/finanshus_om_genmab_vi_siger_det_igen_hvis_du_tror_paa_vores_97_mia_dollar_topsalgsestimat_hvem_bekymrer_sig_saa_om_salget_af_darzalex_for_2019.html?utm_source=forside&utm_campaign=nyhed_03
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind